posted on 2018-04-23, 15:21authored byMuhammad Zubair Israr, Liam M. Heaney, Toru Suzuki
Heart failure (HF) is associated with significant morbidity and mortality. Biomarkers are used to assist clinicians with timely diagnosis, prognosis, and risk prediction of patients for personalized treatment. Using modern proteomic methods such as mass spectrometry, an increasing number of novel biomarkers have been identified that further aid clinicians in the early diagnosis and outcome prediction of HF. This article focuses on the array of common and novel protein-based biomarkers that provide diagnostic and prognostic information in HF.
History
Citation
Heart Failure Clinics, 2018, 14(1), pp. 93-107.
Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Cardiovascular Sciences
The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.